Sanofi's New Diabetes & CV Head Guenter Has Difficult Job Ahead

Sanofi SA's CEO Olivier Brandicourt has shaken up his top management team for the second time since taking over the reins last year, changing the head of its key diabetes franchise in an urgent effort to turn things round. He clearly hopes Peter Guenter's wide-ranging commercial insights can help achieve that.

Peter Guenter
Sanofi's Peter Guenter

Sanofi's chief executive, a French national, has been in the job just over one year and is under pressure to show progress in countering the effects of rising competition and US drug pricing pressures on the diabetes portion of the business, where sales fell 4.5% to €1.73bn ($1.99bn) in the first quarter of this year - a slide that the company predicted in 2015 before reporting a 6.8% drop in diabetes sales for 2015. Sanofi expects sales for the franchise to sink 4% to 8% annually through 2018.

So it's perhaps not surprising that Brandicourt's latest organizational revamp, announced May 23 and which builds on a restructuring unveiled...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip